Outcomes and prognostic predictors of Lu-177 PSMA radioligand therapy in metastatic castration-resistant prostate cancer (Asian Population Study).

Wei Ming ChuaWinnie Wing-Chuen LamAaron Kian-Ti TongRehena SultanaSandra Mei Yu KuaRavindran KanesvaranAlvin Seng Cheong WongKae Jack TayTai Jit Lenith ChengDavid Chee Eng NgSue Ping Thang

Published in: Asia-Pacific journal of clinical oncology (2023)

Our study demonstrated a similar safety and efficacy of Lu-177 PSMA-RLT in Asian mCRPC patients compared to the existing literature. A PSA decline ≥50% was associated with longer OS and PSA PFS. Several prognostic indicators for patient outcomes were also identified.

Keyphrases

prostate cancer
systematic review
pet ct
end stage renal disease
squamous cell carcinoma
small cell lung cancer
chronic kidney disease
ejection fraction
type diabetes
stem cells
peritoneal dialysis
bone marrow
mesenchymal stem cells
insulin resistance
patient reported
cell therapy